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Abstract 
 
 
Red blood cells and reticulocyte parameters were determined on peripheral blood from a 
subset of patients enrolled in the Multicenter Study of Hydroxyuea in sickle cell anemia.   
Multiple blood samples were obtained every two weeks. Cellular indices were measured 
by flow cytometry. Generalized linear models were used to determine the relationship 
between the longitudinal trajectories of red blood cell and reticulocyte indices and 
hydroxyurea usage. There was a significant relationship between hydroxyurea usage and 
most of the red blood cell and reticulocyte indices. Hydroxyurea produced higher value 
trajectories than those generated by placebo usage for the hemoglobin content of both 
the red blood cells and reticulocytes and for the mean corpuscular volume of 
reticulocytes. These changes were first detected 10 weeks after starting hydroxyurea and 
before the increase in hemoglobin F levels. The data suggest that subtle and early 
markers of response to hydroxyurea reside in the hemogram.  
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Introduction 
 
The salutary effects of hydroxyurea (HU) in sickle cell anemia (SS) include decreased 
frequency of painful crises, decreased incidence of acute chest syndrome, decreased 
blood transfusion, and decreased mortality and morbidity (1-5). Markers of the response 
to HU include increased Hb F level, macrocytosis, improved RBC survival and 
deformability, and decreased WBC count (!-7). In this study we report markers of early 
response to HU by using generalized linear mixed models (GLM) to determine the 
relationship between HU usage and the longitudinal trajectories of RBC indices and the 
corresponding longitudinal trajectories of reticulocytes indices. 
 
 
 
 
 
  
Methods 
 
RBC and reticulocyte parameters were determined on peripheral blood from selected 
patients enrolled in the placebo (PL) controlled double blind multicenter study of 
hydroxyuea (MSH) in SS. The study cohort for this analysis consisted of 21 patients from 
the Thomas Jefferson University, Cardeza Foundation for Hematologic Research (10 HU 
subjects, 11 PL subjects). Multiple blood samples were obtained during enrollment in the 
study at a rate of about once every two weeks. The mean weeks of follow-up from 
enrollment date was 86.6 weeks (range 10-172 weeks). The RBC/PLT channel of the 
Siemens H*3 RTX (H*3) hematology analyzer measures the laser light scattered at 2 
different angles by red cells which have been isovolumetrically sphered.  Using the Mie 
theory of light scatter the low angle (2-3o) light intensity directly measures RBC volume 
(MCV, femtoliters) and the high angle (5-15 o) light intensity directly measures refractive 
index which is a linear function of red cell hemoglobin concentration (CHCM, cell 
hemoglobin concentration mean, grams per deciliter).  The Reticulocyte channel reagent 
also isovolumetrically spheres as well as selectively staining the reticulocytes with the 
nucleic acid-binding dye Oxazine 750.  Using the same laser optics and principles as the 
RBC/PLT channel, reticulocyte volume (MCVr, femtoliters) and reticulocyte hemoglobin 
concentration (CHCMr, grams per decilter) are directly measured.  An additional detector 
measures laser light absorption by the Oxazine 750 dye to separate the reticulocytes from 
the mature red cells.  The RBC/PLT channel measures the mean hemoglobin content of 
the red cells (CH) and the reticulocyte channel measures the mean hemoglobin content of 
the reticulocytes (CHr) by multiplying the volume and the cell hemoglobin concentration 
mean.  RBC and Reticulocyte indices were measured on a Siemens H*3 RTX (H*3) 
hematology analyzer. Laser light scattering was used to quantify cell volume, Hb 
concentration, and the light absorbance of cells stained with oxazine 750 to detect 
reticulocytes and distinguish them from mature cells. A total of 20,000 cells were 
counted for each sample. After the volume (V) and Hb concentration (HC) of individual 
mature RBC and reticulocytes were measured, the Hb content (CH) of individual cells 
was calculated (8). 
Generalized linear mixed models (GLM) were used to determine the relationship between 
the longitudinal trajectories of RBC and reticulocyte indices and HU usage (9-12). A 
first-order autoregressive structure was used (1). Information criteria [Akaike Information 
Criterion (AIC)] (13), Akaike Information Criterion, Small Sample Size Corrected 
Version (AICC) (14) and the Bayesian Information Criterion (BIC) (15) were used to 
compare and determine which GLM provided better insight into the relationship between 
the longitudinal trajectories of RBC and reticulocyte indices and HU usage. The 
information criteria are all in “smaller-is-better” form. Since the GLM considered 
longitudinal data,the time at which the longitudinal trajectories were influenced by HU 
usage could also be determined. PROC MIXED (SAS 9.1) was used for the GLM 
analyses. Statistical significance was defined as a 2-sided p-value <.05. 
 Results 
 
The mean weeks (wks) of follow-up from study enrollment date was 86.6 wks (standard 
deviation (sd)=38.84 wks; max=172 wks, median=84 wks, min=10 wks). The mean age 
of this patient cohort at the start of follow-up was 29.0 years (SD =4 .77 years; max=37 
years, median=30 years, min=19 years). There were 13 males (61.9%) and 8 females 
(38.1%). 
 
Goodness-of-fit criteria for the GLM indicated that the RBC indices modeled more 
precisely than those of reticulocytes. However, both the RBC indices and reticulocytes 
provided useful information regarding the relationship between their longitudinal 
trajectories and HU usage (Table 1). 
 
There was a significant relationship between HU usage and the following longitudinal 
trajectories: mean cell hemoglobin (CH) (p<.0001), reticulocyte mean cell hemoglobin 
(CHr) (p<.0001); Cell hemoglobin concentration mean (CHCM) (p=.0394); Reticulocyte 
mean cell volume (MCVr) (p=.0019); hemoglobin distribution width (HDW) (p=.0003) 
and red blood cell volume distribution width (RDW) (p=.0008). HU usage produced 
higher value trajectories than those generated by placebo usage for the following: CH, 
CHr; and MCVr (Fig. 1). These changes were first detected 10 weeks after starting HU 
and before the increase in Hb F levels. 
 
  
 
Discussion 
Although HU has been proven to have salutary effects in patients with SS (1-3) its 
utilization continues to suffer from two major drawbacks. These include its 
underutilization (16) and the fact that at least 25% of patients who take it are non-
responders to its use (1, 2). These two drawbacks seem to re-enforce each other. Thus 
some patients may be falsely labeled as non-responders if no effect on frequency of 
painful crises and/or no increase in the level of Hb F is seen within 2-3 months after 
starting HU at a dose of 10-15 mg/k/day. The reason why some patients do not respond to 
HU is unknown. One possibility is that it fails to recruit dormant bone marrow fetal stem 
cells that are capable to produce fetal Hb. Moreover, it usually takes at least six months 
of therapy with HU before an increase in Hb F is seen (7). Thus an early sign of a 
response-in-progress to HU therapy is important information for the provider who is 
monitoring the the clinical and hematological data of patients after the initiation of 
therapy with HU. 
In this study we report markers of early response to HU by using generalized linear 
mixed models (GLM) to determine the relationship between HU usage and the 
longitudinal trajectories of RBC parameters and the corresponding longitudinal 
trajectories of reticulocytes parameters. Specifically HU therapy showed significant 
changes in the Hb content (CHr) and cell volume of reticulocyte (MCVr) compared to 
placebo within 10 weeks after starting HU indicating an early sign of response to therapy. 
Thus the sequence of signs of response to HU include increase in reticulocyte indices 
(CHr and MCVr) within 10 weeks after therapy followed by increase in RBC indices and 
a later increase (up to six months) in Hb F level. 
 
Conclusion 
 
Together the data suggest that subtle and early markers of response to HU reside in the 
hemogram. This is a fast, simple and inexpensive methodology provided the lab in 
question has the capability to determine the indices of both reticulocytes and RBC.   
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Legend to Figure 1 
Time trends in MCV and MCVr by treatment assignment 
 
 
